Bracco, founded in 1927 by the family who gave it its name and which has been at its helm for three generations and
still runs it today, is an integrated Healthcare Group, world leader in global solutions for the diagnostic imaging field.

Born as a pharmaceuticals trading concern, throughout the decades the Company developed an independent industrial production and research activity, specializing its R&D capacities in a specific field – that of diagnostic imaging: in the 1970's, Bracco's laboratories discovered and developed the iopamidol molecule, the first ready-to-use non-ionic contrast medium.
This important benchmark was followed in 1987 by an internationalization plan that is still underway today.

The Bracco Group has created a leading edge international research network with its three Research Centers located in Geneva, Milan and Princeton, each one highly specialized in different areas and techniques. This network represents perhaps the largest single research structure in the world wholly dedicated to contrast media study and to the development of new products for the sophisticated demands of new diagnostic techniques such as magnetic resonance and sonography.

Healthcare professionals make life and death decisions based upon the education and training they have received. Staying current is critical. Maintaining an environment that provides quality patient care while staying abreast of ever-changing regulations and standards is one of the greatest challenges faced today. Bracco Diagnostics Inc. (BDI) recognizes the importance of designing training and education that meets the unique needs of today's healthcare providers.

BDI is committed to providing a wide array of training and educational tools to the diagnostic community that is centered on topics of practical interest and utility. Ultimately, Bracco strives to improve patient’s lives through the advanced education of imaging professionals.